AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MYGN
  4. [8-K] Myriad Genetics Inc Reports Material Event

[8-K] Myriad Genetics Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Myriad Genetics (MYGN) announced a change in its finance leadership: Scott J. Leffler ceased serving as Chief Financial Officer effective August 15, 2025, and Ben R. Wheeler was appointed CFO effective August 16, 2025. Mr. Wheeler, a 13-year company veteran and CPA, previously held senior finance roles including SVP, Chief Financial Officer, Operations, and SVP, Finance and Treasury. His employment agreement sets an annual base salary of $490,000, an annual target cash bonus of 75% of base salary, standard benefit participation, and an initial equity award totaling 120,000 restricted stock units (60,000 time-based, 60,000 performance/time-based). Mr. Leffler will remain as a non-executive employee briefly to assist the transition.

Myriad Genetics (MYGN) ha comunicato una modifica alla sua direzione finanziaria: Scott J. Leffler ha cessato di ricoprire il ruolo di Chief Financial Officer a decorrere dal 15 agosto 2025, e Ben R. Wheeler 猫 stato nominato CFO a partire dal 16 agosto 2025. Wheeler, vanta 13 anni in azienda ed 猫 CPA; in precedenza ha ricoperto ruoli finanziari di vertice tra cui SVP, Chief Financial Officer, Operations e SVP, Finance and Treasury. Il suo contratto prevede uno stipendio base annuo di $490.000, un bonus annuale target pari al 75% del salario base, la partecipazione ai benefit standard e un premio azionario iniziale di 120.000 restricted stock units (60.000 basate sul tempo, 60.000 legate a performance/tempo). Il signor Leffler rimarr脿 brevemente come dipendente non esecutivo per agevolare la transizione.

Myriad Genetics (MYGN) anunci贸 un cambio en su direcci贸n financiera: Scott J. Leffler dej贸 de desempe帽arse como Chief Financial Officer con efecto el 15 de agosto de 2025, y Ben R. Wheeler fue nombrado CFO con efecto el 16 de agosto de 2025. Wheeler, con 13 a帽os en la empresa y contador p煤blico (CPA), ocup贸 previamente cargos financieros s茅nior, incluidos SVP, Chief Financial Officer, Operations y SVP, Finance and Treasury. Su contrato laboral establece un salario base anual de $490.000, un bono anual objetivo del 75% del salario base, la participaci贸n en los beneficios est谩ndar y una adjudicaci贸n inicial de acciones por un total de 120.000 restricted stock units (60.000 basadas en tiempo, 60.000 basadas en rendimiento/tiempo). El se帽or Leffler permanecer谩 brevemente como empleado no ejecutivo para ayudar en la transici贸n.

Myriad Genetics (MYGN)電� 鞛 毽崝鞁� 氤�瓴届潉 氚滍憸頄堨姷雼堧嫟. Scott J. Leffler電� 2025雲� 8鞗� 15鞚茧秬搿� 斓滉碃鞛毂呾瀯鞛�(CFO) 鞛愲Μ鞐愳劀 氍茧煬雮碃, Ben R. Wheeler臧� 2025雲� 8鞗� 16鞚茧秬搿� CFO搿� 鞛勲獏霅橃棃鞀惦媹雼�. Wheeler電� 須岇偓鞐愳劀 13雲� 攴茧頃� 瓿奠澑須岅硠靷�(CPA)搿�, 鞚挫爠鞐� SVP, Chief Financial Officer, Operations 氚� SVP, Finance and Treasury 霌� 瓿犾渼 鞛 歆侅眳鞚� 毵§晿鞀惦媹雼�. 攴胳潣 瓿犾毄瓿勳暯靹滌棎電� 鞐瓣皠 旮半掣旮� $490,000, 旮半掣旮夓潣 75%鞐� 頃措嫻頃橂姅 鞐瓣皠 氇╉憸 順勱笀 氤措剤鞀�, 響滌 氤惦Μ頉勳儩 彀胳棳 氚� 齑� 120,000臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(restricted stock units)鞚� 齑堦赴 歆�攵� 氤挫儊(鞁滉皠旮半皹 60,000, 靹标臣/鞁滉皠 順柬暕 60,000)鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Leffler 鞌姅 鞝勴櫂鞚� 歆�鞗愴晿旮� 鞙勴暣 鞛犾嫓 牍勳瀯鞗� 歆侅洂鞙茧 雮晞 鞛堨潉 鞓堨爼鞛呺媹雼�.

Myriad Genetics (MYGN) a annonc茅 un changement 脿 la t锚te de ses finances聽: Scott J. Leffler a cess茅 d'exercer la fonction de Chief Financial Officer 脿 compter du 15 ao没t 2025, et Ben R. Wheeler a 茅t茅 nomm茅 CFO 脿 compter du 16 ao没t 2025. M. Wheeler, employ茅 de l'entreprise depuis 13 ans et CPA, a pr茅c茅demment occup茅 des postes financiers sup茅rieurs, notamment SVP, Chief Financial Officer, Operations et SVP, Finance and Treasury. Son contrat de travail pr茅voit un salaire de base annuel de $490鈥�000, une prime annuelle cible de 75% du salaire de base, la participation aux avantages standards et une attribution initiale d'actions repr茅sentant au total 120鈥�000 restricted stock units (60鈥�000 bas茅es sur le temps, 60鈥�000 li茅es 脿 la performance/au temps). M. Leffler restera bri猫vement en tant qu'employ茅 non ex茅cutif pour faciliter la transition.

Myriad Genetics (MYGN) gab eine 脛nderung in der Finanzf眉hrung bekannt: Scott J. Leffler trat mit Wirkung zum 15. August 2025 nicht l盲nger als Chief Financial Officer zur眉ck, und Ben R. Wheeler wurde mit Wirkung zum 16. August 2025 zum CFO ernannt. Wheeler ist seit 13 Jahren im Unternehmen und CPA; zuvor bekleidete er leitende Finanzpositionen, darunter SVP, Chief Financial Officer, Operations sowie SVP, Finance and Treasury. Sein Arbeitsvertrag sieht ein j盲hrliches Grundgehalt von $490.000, eine j盲hrliche Zielbarpr盲mie von 75% des Grundgehalts, die Teilnahme an den 眉blichen Leistungen sowie eine anf盲ngliche Aktienzuteilung in H枚he von insgesamt 120.000 Restricted Stock Units vor (60.000 zeitbasiert, 60.000 leistungs-/zeitbasiert). Herr Leffler bleibt f眉r kurze Zeit als nicht gesch盲ftsf眉hrender Mitarbeiter, um den 脺bergang zu unterst眉tzen.

Positive
  • Internal promotion of Ben R. Wheeler preserves institutional knowledge and continuity in finance leadership
  • Extensive experience: 13 years at the company with progressive senior finance roles and CPA qualification
  • Transition plan: Former CFO to remain temporarily as a non-executive employee to assist handover
Negative
  • Departure of prior CFO (Scott J. Leffler) may raise short-term investor questions about leadership changes
  • Significant initial equity award (120,000 RSUs) could increase non-cash compensation expense and eventual dilution

Insights

TL;DR: Internal promotion preserves continuity but large equity award warrants shareholder attention.

The Board promoted an internal finance executive, which supports continuity in financial reporting and treasury operations given Mr. Wheeler's long tenure and progressive responsibilities. The employment package aligns incentives through cash bonus and equity, but the 120,000 RSU initial grant is meaningful and should be reviewed relative to outstanding shares and executive pay practices. Retention of the departing CFO as a transitional non-executive employee reduces operational risk during handover.

TL;DR: Operational continuity likely maintained; monitor compensation expense and any near-term financial disclosures.

Mr. Wheeler's appointment from within suggests limited disruption to ongoing financial operations. Compensation details鈥�$490,000 base and 75% target bonus鈥攁re standard for a Fortune-/mid-cap biotech CFO, but the size and structure of the equity grant could increase non-cash compensation expense and modestly dilute shareholders when vested. No forward-looking financial guidance or material transactions were disclosed in this filing.

Myriad Genetics (MYGN) ha comunicato una modifica alla sua direzione finanziaria: Scott J. Leffler ha cessato di ricoprire il ruolo di Chief Financial Officer a decorrere dal 15 agosto 2025, e Ben R. Wheeler 猫 stato nominato CFO a partire dal 16 agosto 2025. Wheeler, vanta 13 anni in azienda ed 猫 CPA; in precedenza ha ricoperto ruoli finanziari di vertice tra cui SVP, Chief Financial Officer, Operations e SVP, Finance and Treasury. Il suo contratto prevede uno stipendio base annuo di $490.000, un bonus annuale target pari al 75% del salario base, la partecipazione ai benefit standard e un premio azionario iniziale di 120.000 restricted stock units (60.000 basate sul tempo, 60.000 legate a performance/tempo). Il signor Leffler rimarr脿 brevemente come dipendente non esecutivo per agevolare la transizione.

Myriad Genetics (MYGN) anunci贸 un cambio en su direcci贸n financiera: Scott J. Leffler dej贸 de desempe帽arse como Chief Financial Officer con efecto el 15 de agosto de 2025, y Ben R. Wheeler fue nombrado CFO con efecto el 16 de agosto de 2025. Wheeler, con 13 a帽os en la empresa y contador p煤blico (CPA), ocup贸 previamente cargos financieros s茅nior, incluidos SVP, Chief Financial Officer, Operations y SVP, Finance and Treasury. Su contrato laboral establece un salario base anual de $490.000, un bono anual objetivo del 75% del salario base, la participaci贸n en los beneficios est谩ndar y una adjudicaci贸n inicial de acciones por un total de 120.000 restricted stock units (60.000 basadas en tiempo, 60.000 basadas en rendimiento/tiempo). El se帽or Leffler permanecer谩 brevemente como empleado no ejecutivo para ayudar en la transici贸n.

Myriad Genetics (MYGN)電� 鞛 毽崝鞁� 氤�瓴届潉 氚滍憸頄堨姷雼堧嫟. Scott J. Leffler電� 2025雲� 8鞗� 15鞚茧秬搿� 斓滉碃鞛毂呾瀯鞛�(CFO) 鞛愲Μ鞐愳劀 氍茧煬雮碃, Ben R. Wheeler臧� 2025雲� 8鞗� 16鞚茧秬搿� CFO搿� 鞛勲獏霅橃棃鞀惦媹雼�. Wheeler電� 須岇偓鞐愳劀 13雲� 攴茧頃� 瓿奠澑須岅硠靷�(CPA)搿�, 鞚挫爠鞐� SVP, Chief Financial Officer, Operations 氚� SVP, Finance and Treasury 霌� 瓿犾渼 鞛 歆侅眳鞚� 毵§晿鞀惦媹雼�. 攴胳潣 瓿犾毄瓿勳暯靹滌棎電� 鞐瓣皠 旮半掣旮� $490,000, 旮半掣旮夓潣 75%鞐� 頃措嫻頃橂姅 鞐瓣皠 氇╉憸 順勱笀 氤措剤鞀�, 響滌 氤惦Μ頉勳儩 彀胳棳 氚� 齑� 120,000臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(restricted stock units)鞚� 齑堦赴 歆�攵� 氤挫儊(鞁滉皠旮半皹 60,000, 靹标臣/鞁滉皠 順柬暕 60,000)鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Leffler 鞌姅 鞝勴櫂鞚� 歆�鞗愴晿旮� 鞙勴暣 鞛犾嫓 牍勳瀯鞗� 歆侅洂鞙茧 雮晞 鞛堨潉 鞓堨爼鞛呺媹雼�.

Myriad Genetics (MYGN) a annonc茅 un changement 脿 la t锚te de ses finances聽: Scott J. Leffler a cess茅 d'exercer la fonction de Chief Financial Officer 脿 compter du 15 ao没t 2025, et Ben R. Wheeler a 茅t茅 nomm茅 CFO 脿 compter du 16 ao没t 2025. M. Wheeler, employ茅 de l'entreprise depuis 13 ans et CPA, a pr茅c茅demment occup茅 des postes financiers sup茅rieurs, notamment SVP, Chief Financial Officer, Operations et SVP, Finance and Treasury. Son contrat de travail pr茅voit un salaire de base annuel de $490鈥�000, une prime annuelle cible de 75% du salaire de base, la participation aux avantages standards et une attribution initiale d'actions repr茅sentant au total 120鈥�000 restricted stock units (60鈥�000 bas茅es sur le temps, 60鈥�000 li茅es 脿 la performance/au temps). M. Leffler restera bri猫vement en tant qu'employ茅 non ex茅cutif pour faciliter la transition.

Myriad Genetics (MYGN) gab eine 脛nderung in der Finanzf眉hrung bekannt: Scott J. Leffler trat mit Wirkung zum 15. August 2025 nicht l盲nger als Chief Financial Officer zur眉ck, und Ben R. Wheeler wurde mit Wirkung zum 16. August 2025 zum CFO ernannt. Wheeler ist seit 13 Jahren im Unternehmen und CPA; zuvor bekleidete er leitende Finanzpositionen, darunter SVP, Chief Financial Officer, Operations sowie SVP, Finance and Treasury. Sein Arbeitsvertrag sieht ein j盲hrliches Grundgehalt von $490.000, eine j盲hrliche Zielbarpr盲mie von 75% des Grundgehalts, die Teilnahme an den 眉blichen Leistungen sowie eine anf盲ngliche Aktienzuteilung in H枚he von insgesamt 120.000 Restricted Stock Units vor (60.000 zeitbasiert, 60.000 leistungs-/zeitbasiert). Herr Leffler bleibt f眉r kurze Zeit als nicht gesch盲ftsf眉hrender Mitarbeiter, um den 脺bergang zu unterst眉tzen.

0000899923false00008999232025-08-152025-08-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  August 15, 2025
 
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware 0-26642 87-0494517
(State or other jurisdiction of
incorporation)		 (Commission
File Number)		 (IRS Employer
Identification No.)
 
322 North 2200 West
Salt Lake City, Utah 84116
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading
Symbol(s)		 Name of each exchange on which registered
Common Stock, $0.01 par value MYGN Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Scott J. Leffler as Chief Financial Officer

On August 18, 2025, Myriad Genetics, Inc. (the “Company”) announced that, effective August 15, 2025, Scott J. Leffler no longer serves as Chief Financial Officer of the Company. Mr. Leffler is expected to remain as a non-executive employee of the Company for an interim period to assist in the transition of his responsibilities.

Appointment of Ben R. Wheeler as Chief Financial Officer

On August 14, 2025, the Company’s Board of Directors (the “Board”) appointed Ben R. Wheeler, currently serving as the Company’s Senior Vice President, Chief Financial Officer, Operations, as the Company’s Chief Financial Officer and principal financial officer, effective August 16, 2025. Mr. Wheeler’s appointment as Chief Financial Officer was announced by the Company via press release on August 18, 2025.

Mr. Wheeler, 42, has served in various roles of increasing responsibility at the Company over the past thirteen years, including most recently as Senior Vice President, Chief Financial Officer, Operations, since June 2022, and Senior Vice President, Finance and Treasury, since July 2020. Mr. Wheeler has also served at the Company as Senior Vice President, Accounting, from June 2018 to July 2020, Vice President, Corporate Controller, from December 2014 to June 2018, and in other controllership positions from December 2011 to December 2014. Before joining the Company, Mr. Wheeler served as an auditor for Ernst & Young. Mr. Wheeler holds both master’s and bachelor’s degrees in accounting from Brigham Young University and is a Certified Public Accountant.

There are no arrangements or understandings between Mr. Wheeler and any other person pursuant to which he was appointed as an officer of the Company. Mr. Wheeler does not have any family relationship with any director or other executive officer of the Company and is not party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K.

In connection with his appointment, the Company entered into an employment agreement with Mr. Wheeler, dated August 14, 2025 (the “Employment Agreement”), setting forth the terms of Mr. Wheeler’s employment, including his compensation and the commencement of his employment as Chief Financial Officer on August 16, 2025 (the “Commencement Date”). Pursuant to the Employment Agreement, Mr. Wheeler will be paid an annual base salary of $490,000. Mr. Wheeler will be eligible to receive an annual target cash bonus equal to 75% of his annual base salary upon achievement of goals to be established by the Compensation and Human Capital Committee of the Board (the “CHCC”) or the Chief Executive Officer each fiscal year and will be eligible to participate in the Company’s annual long-term incentive compensation program. Mr. Wheeler will also be eligible to participate in the standard health, welfare and retirement benefit plans that are applicable to similarly situated executives of the Company. The Employment Agreement also provides for an initial one-time grant of restricted stock units (the "Initial Grant") to Mr. Wheeler in connection with his promotion. The Initial Grant was granted on the Commencement Date and consisted of (i) 60,000 restricted stock units, subject to standard time-based vesting, and (ii) 60,000 restricted stock units, subject to vesting upon satisfaction of certain performance metrics and standard time-based vesting, as determined by the CHCC in its sole discretion, and subject to Mr. Wheeler’s continued service to the Company through the applicable vesting dates.

The Company and Mr. Wheeler also entered into the Company's standard Employee Invention Assignment, Confidentiality, and Restrictive Covenants Agreement, Severance and Change of Control Agreement and Indemnification Agreement.

The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by the full text of such agreement, a copy of which will be filed with the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025.

ITEM 7.01 Regulation FD Disclosure.

A copy of the press release announcing Mr. Leffler’s departure and Mr. Wheeler’s appointment as Chief Financial Officer and principal financial officer on the Commencement Date is furnished as Exhibit 99.1 to this Current Report on Form 8-K.


ITEM 9.01    Financial Statements and Exhibits.

Exhibit
Number		 Description
99.1
Press Release dated August 18, 2025.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
MYRIAD GENETICS, INC.
Date: August 18, 2025By:
/s/ Benjamin Richard Wheeler
Benjamin Richard Wheeler
Chief Financial Officer



Source:

FAQ

Who is the new CFO of Myriad Genetics (MYGN)?

Ben R. Wheeler was appointed Chief Financial Officer effective August 16, 2025.

What compensation was disclosed for the new MYGN CFO?

Mr. Wheeler's Employment Agreement provides an annual base salary of $490,000, an annual target cash bonus of 75% of base salary, and participation in standard benefit plans.

Did the filing describe any equity awards for the new CFO?

Yes. An initial grant of 120,000 restricted stock units was awarded on the commencement date: 60,000 time-based RSUs and 60,000 RSUs subject to performance metrics and time-based vesting.

Will the former CFO remain with MYGN after his resignation as CFO?

Yes. Scott J. Leffler is expected to remain as a non-executive employee for an interim period to assist the transition.

Are there any related-party or family relationships disclosed for the new CFO?

No. The filing states Mr. Wheeler does not have any family relationship with directors or executive officers and is not party to related-party transactions requiring disclosure.
Stock MYGN logo
Myriad Genetics

NASDAQ:MYGN

MYGN Rankings

#3218 Ranked by Market Cap
N/A Ranked by Dividends
#175 Top Gainer

MYGN Latest News

Aug 27, 2025
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Aug 20, 2025
ANGLE Announces Collaboration with Myriad Genetics
Aug 18, 2025
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Aug 13, 2025
New Myriad Genetics Survey Uncovers Women Fear Screenings鈥擝ut Feel Reassured by the Results
Aug 5, 2025
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

MYGN Latest SEC Filings

Aug 19, 2025
[Form 4] Myriad Genetics Inc Insider Trading Activity
Aug 19, 2025
[Form 3] Myriad Genetics Inc Initial Statement of Beneficial Ownership
Aug 18, 2025
[Form 4] Myriad Genetics Inc Insider Trading Activity
Aug 14, 2025
[SCHEDULE 13G/A] Myriad Genetics Inc SEC Filing
Aug 12, 2025
[SCHEDULE 13G] Myriad Genetics Inc SEC Filing

MYGN Stock Data

540.59M
89.95M
2.84%
98.32%
9.13%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
United States
SALT LAKE CITY